4-Antibody AG
Country
Switzerland
Краткое название
4-Antibody AG
Headquarters
Hochbergerstrasse 60C
Members of the board
Robert F Burns, PhD, Chief Executive Officer
Marc van Dijk, PhD, Chief Technology Officer
Luis Martin-Parras, PhD, Head of Research & Development and Administration
Melanie Schmid, Head of Human Resources
Eva-Maria Stegemann, PhD, M&A Program Director
Andreas Richter, Financial Consultant
Marc van Dijk, PhD, Chief Technology Officer
Luis Martin-Parras, PhD, Head of Research & Development and Administration
Melanie Schmid, Head of Human Resources
Eva-Maria Stegemann, PhD, M&A Program Director
Andreas Richter, Financial Consultant
Categories medicine
Oncology, Infectious diseases
Stage of the project
Production
Disease
Viral hepatitis, Breast cancer
Current owners
Max Burger, MD, PhD, Chairman
Shahzad Malik, MD, General Partner, Advent Venture Partners
Fritz Melchers, PhD, Senior Research Group Leader, Max-Planck-Institut Berlin
Gerhard Ries, PhD, Co-Founder and General Partner, BioMedInvest/BioMedCredit
Thomas von R"uden, PhD, formerly CEO, DIREVO Industrial Biotechnology GmbH, Cologne, Germany
Erich Rauschenbusch, Partner, Grazia Equity GmbH
Joachim Rothe, PhD, General Partner, Life Science Partners
Shahzad Malik, MD, General Partner, Advent Venture Partners
Fritz Melchers, PhD, Senior Research Group Leader, Max-Planck-Institut Berlin
Gerhard Ries, PhD, Co-Founder and General Partner, BioMedInvest/BioMedCredit
Thomas von R"uden, PhD, formerly CEO, DIREVO Industrial Biotechnology GmbH, Cologne, Germany
Erich Rauschenbusch, Partner, Grazia Equity GmbH
Joachim Rothe, PhD, General Partner, Life Science Partners
Technology
Cell Technologies, Homogeneous antibodies, Technologies, Pharmaceuticals